Viridian Therapeutics, Inc. (VRDN) Stock Analysis

Q: What is the VRDN stock price target?

Take-profit $30.21 (+127.0% upside). Prior stop was $12.78.

Q: What are the risks of investing in VRDN?

Concentration risk — Pipeline: veligrotug; Quality below floor (1.7 < 4.0); Quality below floor (1.7 < 4.0); EARNINGS_PROXIMITY:6d<=7d.

Q: Is VRDN overvalued or undervalued?

Viridian Therapeutics, Inc. trades at a P/E of N/A (forward -5.5). TrendMatrix value score: 5.4/10. Overall verdict: Sell.

Q: What do analysts say about VRDN?

25 analysts cover VRDN with a consensus score of 4.2/5. Average price target: $34.

SellVALUE-TRAP 1/5Moderate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

Earnings in 6 days (2026-05-06). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Viridian Therapeutics is a clinical-stage biopharmaceutical company developing IGF-1R inhibitors for thyroid eye disease (TED). Lead programs: veligrotug (IV, Phase 3 THRIVE/THRIVE-2 completed/enrolling) and elegrobart (SC, Phase 3 REVEAL-1/REVEAL-2 enrolling). The company has... Read more

$13.37+127.0% A.UpsideScore 5.5/10#41 of 158 Biotechnology

Stop $12.78Target $30.21(analyst − 10%)A.R:R 14.3:1

Analyst target$33.56+151.0%16 analysts

$30.21our TP

$13.37price

$33.56mean

$50

Sell if holding. Engine safety override at $13.37: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 14.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality; Below long-term trend. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.5/10, moderate confidence.

Passes 6/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on earnings proximity 6d<=7d. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Concentration risk — Pipeline: veligrotug

Quality below floor (1.7 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-5.5

Mkt Cap$1.4B

EV/EBITDA-1.8

Profit Mgn0.0%

ROE-49.2%

Rev Growth83.3%

Beta1.17

DividendNone

Rating analysts25

Quality Signals

Piotroski F3/9

Options Flow

P/C0.37bullish

IV107%elevated

Max Pain$1-92.5% vs spot

Concentration Risks(10-K Item 1A)

HIGHpipelineveligrotug
10-K Item 1A: 'We expect that the THRIVE and THRIVE-2 phase 3 clinical trials ... will support global health authority registration for veligrotug'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value5.415%0.81

Quality1.715%0.26

Growth10.015%1.50

Momentum4.810%0.48

Sentiment8.110%0.81

Insider Activity5.010%0.50

Peer Rank3.410%0.34

Technical Setup5.85%0.29

Risk Profile4.15%0.20

Catalyst6.75%0.34

Overall (Σ contributions)5.53

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Gross Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

3.3

Current Ratio

5.0

Moat

5.0

Cash-burning: FCF -229% of revenueNo competitive moatWeak Piotroski F-Score: 3/9Quality concerns

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

2.4

Value Rank

2.7

Growth Rank

7.9

GatesEARNINGS PROXIMITY 6d<=7dMomentum 4.8<5.5 (soft — BUY_NOW allowed but watch)Momentum 4.8>=4.5A.R:R 14.3 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARSuitability: Aggressive

RSI

23 · Oversold

↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $13.18Resistance $19.25

Price Targets

$13

$30

A.Upside+126.0%

A.R:R14.3:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (1.7 < 4.0)

! EARNINGS_PROXIMITY:6d<=7d

Earnings

3/4 beats

Next Earnings2026-05-06 (6d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is VRDN stock a buy right now?

Sell if holding. Engine safety override at $13.37: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 14.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality; Below long-term trend. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $12.78. Score 5.5/10, moderate confidence.

What is the VRDN stock price target?

Take-profit target: $30.21 (+127.0% upside). Prior stop was $12.78. Stop-loss: $12.78.

What are the risks of investing in VRDN?

Concentration risk — Pipeline: veligrotug; Quality below floor (1.7 < 4.0).

Is VRDN overvalued or undervalued?

Viridian Therapeutics, Inc. trades at a P/E of N/A (forward -5.5). TrendMatrix value score: 5.4/10. Verdict: Sell.

What do analysts say about VRDN?

25 analysts cover VRDN with a consensus score of 4.2/5. Average price target: $34.

What does Viridian Therapeutics, Inc. do?Viridian Therapeutics is a clinical-stage biopharmaceutical company developing IGF-1R inhibitors for thyroid eye...